LY4100511

DC-853 · DICE Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY4100511, covering 2025-01-24 to 2025-01-24. Get the full timeline:

Most recent: Clinical Trial Update: A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants [Phase 1]

See pricing